{"id":754987,"date":"2023-05-04T10:45:07","date_gmt":"2023-05-04T14:45:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\/"},"modified":"2023-05-04T10:45:07","modified_gmt":"2023-05-04T14:45:07","slug":"eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\/","title":{"rendered":"Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting"},"content":{"rendered":"
\n

\n Eterna to present data on iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting, nucleic-acid delivery, and targeted gene insertion<\/em>\n <\/p>\n

CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) — Eterna Therapeutics Inc.<\/a> (Nasdaq: ERNA<\/a>) (\u201cEterna\u201d or the \u201cCompany\u201d), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced it will deliver eight presentations showcasing its mRNA cell engineering platform at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 16-20, 2023 at the Los Angeles Convention Center.<\/p>\n

Susan McClatchey, Vice President, Quality at Eterna Therapeutics, will participate in a fireside chat, hosted by Citeline, about the manufacturing of gene therapies.<\/p>\n

\n Title<\/strong>: Overcoming the Manufacturing and Regulatory Challenges for Gene Therapies
Date\/Time: <\/strong>May 17, Doors open 6:00 PM PT
Speaker: <\/strong>Susan McClatchey, Vice President, Quality at Eterna Therapeutics
Location: <\/strong>Grammy Museum, 800 W Olympic Blvd, Los Angeles, CA 90015<\/p>\n

Details of Eterna\u2019s poster presentations are below, including several posters presented by or in conjunction with Eterna\u2019s discovery partner, Factor Bioscience.<\/p>\n

\n Title: <\/strong>Rational Design of Multivalent Ionizable Lipid Delivery Systems for mRNA Delivery to Blood Cells
Abstract & Poster Board Number: <\/strong>563<\/a>
Presenter: <\/strong>Elizabeth Belcher, Research Associate I at Eterna Therapeutics
Session & Location: <\/strong>Wednesday Poster Session,\u00a0<\/strong>West Hall A
Date\/Time: <\/strong>May 17, 12:00-2:00 PM PT<\/p>\n

\n Title: <\/strong>A Scalable, iPS Cell Derived Lymphocyte and Myeloid Multi-Cell-Type Therapeutic Platform for Enhanced Tumor Cell Killing*
Abstract & Poster Board Number: <\/strong>616<\/a>
Presenter: <\/strong>Abigail J. Blatchford, Associate Scientist at Factor Bioscience
Session & Location: <\/strong>Wednesday Poster Session, West Hall A
Date\/Time: <\/strong>May 17, 12:00-2:00 PM PT<\/p>\n

\n Title: <\/strong>Chemically Modified Single-Stranded DNA Donors Enable Efficient mRNA Gene Editing-Mediated Knock-In in Human iPS Cells*
Abstract & Poster Board Number: <\/strong>1065<\/a>
Presenter: <\/strong>Claire Aibel, Associate Scientist at Factor Bioscience
Session & Location: <\/strong>Thursday Poster Session, West Hall A
Date\/Time: <\/strong>May 18, 12:00-2:00 PM PT<\/p>\n

\n Title: <\/strong>Efficient Transgene Knock-In in Human iPS Cells Combined with Small Molecule-Mediated \u201cOn-Switch\u201d Yields Clonal Populations of Engineered Tissue-Specific Cells*
Abstract & Poster Board Number: <\/strong>1103<\/a>
Presenter: <\/strong>Taeyun Kim, Associate Scientist at Factor Bioscience
Session & Location: <\/strong>Thursday Poster Session, West Hall A
Date\/Time: <\/strong>May 18, 12:00-2:00 PM PT<\/p>\n

\n Title: <\/strong>Novel Ionizable Lipids Derived from 2-Hydroxypropylamine and Spermine for mRNA-LNP Delivery*
Abstract & Poster Board Number: <\/strong>1262<\/a>
Presenter: <\/strong>Ariadna Lubinus, Associate Scientist at Factor Bioscience
Session & Location: <\/strong>Friday Poster Session, West Hall A
Date\/Time: <\/strong>May 19, 12:00-2:00 PM PT<\/p>\n

\n Title: <\/strong>Directed Differentiation of Gene Edited iPSCs by Small-Molecule Inhibition of a Transgene-Encoded Protein
Abstract & Poster Board Number: <\/strong>1314<\/a>
Presenter: <\/strong>Raven Dance Klee, Research Associate II at Eterna Therapeutics
Session & Location: <\/strong>Friday Poster Session, West Hall A
Date\/Time: <\/strong>May 19, 12:00-2:00 PM PT<\/p>\n

\n Title: <\/strong>Gene Editing Proteins with Nickase Functionality Enable Scarless Targeted Gene Insertion in Primary Human Cells
Abstract & Poster Board Number: <\/strong>1516<\/a>
Presenter: <\/strong>Elizabeth Belcher, Research Associate I at Eterna Therapeutics
Session & Location: <\/strong>Friday Poster Session, West Hall A
Date\/Time: <\/strong>May 19, 12:00-2:00 PM PT<\/p>\n

\n Title: <\/strong>mRNA Cell Engineering Enables Rapid Prototyping of Macrophage Gene-Editing Strategies for Cancer Immunotherapy Applications*
Abstract & Poster Board Number: <\/strong>1563<\/a>
Presenter:<\/strong> Ian Hay, Associate Scientist at Factor Bioscience
Session & Location: <\/strong>Friday Poster Session, West Hall A
Date\/Time: <\/strong>May 19, 12:00-2:00 PM PT<\/p>\n

Abstracts are available on the ASGCT Annual Meeting website here<\/a>.<\/p>\n

*Research conducted and presented by discovery partner Factor Bioscience.<\/p>\n

\n About Eterna Therapeutics Inc.<\/strong>
\n
Eterna Therapeutics is a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines. Eterna has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice\u2122 and UltraSlice\u2122 gene-editing proteins, and the ToRNAdo\u2122 mRNA delivery system from Factor Bioscience. NoveSlice\u2122, UltraSlice\u2122, and ToRNAdo\u2122 are trademarks of Factor Bioscience. For more information, please visit\u00a0www.eternatx.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are any statements that are not statements of historical fact and may be identified by terminology such as \u201cbelieve,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cproject,\u201d \u201cwill\u201d or other similar words and the negatives of such words. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those stated or implied in any forward-looking statement as a result of various factors, including, but not limited to, uncertainties related to: (i) the evolution of Eterna\u2019s business model into a platform company focused on mRNA, iPS cell and gene editing technologies; (ii) Eterna\u2019s ability to successfully, cost-effectively and efficiently develop its technology and products; (iii) Eterna\u2019s ability to successfully commence clinical trials of any products on a timely basis or at all; (iv) Eterna\u2019s ability to successfully fund and manage the growth of its development activities; and (v) Eterna \u2019s ability to obtain regulatory approvals of its products for commercialization. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this communication speak only as of the date on which they were made, and Eterna does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law. Factors that may cause Eterna\u2019s actual results to differ from those expressed or implied in forward-looking statements contained in this press release are more fully disclosed in Eterna\u2019s periodic public filings with the U.S. Securities and Exchange Commission, particularly under the heading \u201cRisk Factors\u201d in Eterna\u2019s Annual Report on Form 10-K for the year ended December 31, 2022, as well as under similar headings in Eterna\u2019s subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.<\/p>\n

\n Investor Relations Contact:<\/strong>
\n
\n
\n investors@eternatx.com<\/u>
\n <\/a>\n <\/p>\n

\n Media Contact:<\/strong>
\n
\n
\n EternaPR@westwicke.com<\/u>
\n <\/a>\n <\/p>\n

\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Eterna to present data on iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting, nucleic-acid delivery, and targeted gene insertion CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) — Eterna Therapeutics Inc. (Nasdaq: ERNA) (\u201cEterna\u201d or the \u201cCompany\u201d), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced it will deliver eight presentations showcasing its mRNA cell engineering platform at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 16-20, 2023 at the Los Angeles Convention Center. Susan McClatchey, Vice President, Quality at Eterna Therapeutics, will participate in a fireside chat, hosted by Citeline, about the manufacturing of gene therapies. Title: Overcoming the Manufacturing and … <\/p>\n

Continue reading “Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-754987","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Eterna to present data on iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting, nucleic-acid delivery, and targeted gene insertion CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) — Eterna Therapeutics Inc. (Nasdaq: ERNA) (\u201cEterna\u201d or the \u201cCompany\u201d), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced it will deliver eight presentations showcasing its mRNA cell engineering platform at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 16-20, 2023 at the Los Angeles Convention Center. Susan McClatchey, Vice President, Quality at Eterna Therapeutics, will participate in a fireside chat, hosted by Citeline, about the manufacturing of gene therapies. Title: Overcoming the Manufacturing and … Continue reading "Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-04T14:45:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTc1OCM1NTc0NTgxIzIyMTAyODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting\",\"datePublished\":\"2023-05-04T14:45:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\\\/\"},\"wordCount\":1025,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTc1OCM1NTc0NTgxIzIyMTAyODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\\\/\",\"name\":\"Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTc1OCM1NTc0NTgxIzIyMTAyODA=\",\"datePublished\":\"2023-05-04T14:45:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTc1OCM1NTc0NTgxIzIyMTAyODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTc1OCM1NTc0NTgxIzIyMTAyODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting - Market Newsdesk","og_description":"Eterna to present data on iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting, nucleic-acid delivery, and targeted gene insertion CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) — Eterna Therapeutics Inc. (Nasdaq: ERNA) (\u201cEterna\u201d or the \u201cCompany\u201d), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced it will deliver eight presentations showcasing its mRNA cell engineering platform at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 16-20, 2023 at the Los Angeles Convention Center. Susan McClatchey, Vice President, Quality at Eterna Therapeutics, will participate in a fireside chat, hosted by Citeline, about the manufacturing of gene therapies. Title: Overcoming the Manufacturing and … Continue reading \"Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-04T14:45:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTc1OCM1NTc0NTgxIzIyMTAyODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting","datePublished":"2023-05-04T14:45:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\/"},"wordCount":1025,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTc1OCM1NTc0NTgxIzIyMTAyODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\/","name":"Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTc1OCM1NTc0NTgxIzIyMTAyODA=","datePublished":"2023-05-04T14:45:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTc1OCM1NTc0NTgxIzIyMTAyODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTc1OCM1NTc0NTgxIzIyMTAyODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eterna-therapeutics-to-deliver-eight-presentations-at-the-american-society-of-gene-cell-therapy-asgct-26th-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=754987"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754987\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=754987"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=754987"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=754987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}